Paydirt
S
Insider

Sanofi

10% owner

Sanofi (10% owner) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Attovia Therapeutics, Inc. Common Stock (ATTO). Across 1 priced purchase filing, the average 21-session return was +9.8% from execution and +27.1% from disclosure (delay-adjusted; derived). The largest single filing was $5.1M of ATTO (300,000 sh × $17.00, as filed), executed Aug 6.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
+9.8%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+27.1%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$5.1M
shares × price, as filed
Last traded
Aug 6
Filed Aug 7
Open performance
Volume by month
$5.1M$2.5M$0Oct 2024Apr 2025Oct 2025Apr 2026Aug 2026 · buys $5.1M
Buys $5.1M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names
ATTO Attovia Therapeutics, Inc. Common Stock ATTO · 1 buy · 0 sells 1 filing
Recent filings
ATTOPURCHASE Attovia Therapeutics, Inc. Common Stock View filing → $5.1M
300,000 sh × $17.00
Exec Aug 6
Filed Aug 7 · 3:45 PM ET